France ranks third in Europe, behind the United Kingdom and Germany, in the number of biotechnology companies operating within its territory. With 400 firms employing about 6,000 people, more than half of whom work in research and development. (Source)
Here are my picks for innovative biotechs in France.
Novilase, Evry, is a leading company in image-guided laser tumor therapy. Their vision is to establish laser therapy as a treatment alternative to surgery for tumors, benefiting the patient. Currently Novian Health is focused on providing women with a minimally invasive alternative to surgery for cancerous and non-cancerous breast tumors. The Novilase laser procedure is performed in a breast center with ultrasound imaging guidance in a manner similar to a breast biopsy.
Adocia, Lyon, BioChaperone® system optimizes the performance of therapeutic proteins. BioChaperone® is a Molecular Delivery System for Therapeutic Proteins.Adocia designed the BioChaperone® platform technology from innovative polymers, oligomers and small organic compounds. By forming a physical complex with proteins, BioChaperone® protects them from enzymatic degradation and enhances their performance.
BioChaperone® improves “chaperoned” proteins’ efficiency through its stabilizing and solubilizing effects:
- Acceleration of action and modification of action duration
- Enhancement of absorption and bioavailability
- Decreased dosage and frequency of administration
OSE Immuno Therapeutics, Nantes, is a clinical-stage biotechnology company in immunotherapy. They are focused on developing and partnering therapies to control the immune system for immuno-oncology and autoimmmune diseases.
Three areas of expertise are being developed within our immunology research platform:
- T-cell based vaccination
- Immuno-Oncology (focus on myeloid targets)
- Auto-Immunity & Inflammation
Mnemo, Paris, is using its EnfiniT platform, an integrated drug discovery engine that combines:
- A proprietary combination of epigenetics tools assembled into powerful T cell engineering technologies
- A revolutionary target ID engine that sources newly-identified junctions between exons and transposable elements (JETs)
- Best-in-class manufacturing
Mnemo will transform the body’s immune response to overcome currently incurable diseases.
Genclis SA, Vandoeuvre-lès-Nancy, is a biotechnology company focused on developing therapies for both human and animal health using Transcription Infidelity (“TI”). TI is a patented process that begins by analyzing differences between RNA and DNA sequences to identify translated proteins capable of causing the production of either Immunoglobulin E (“IgE”), the antibody responsible for most forms of allergies or Immunoglobulin G (“IgG”), the workhorse of immunity that accounts for most of vaccine efficacy. Genclis uses its proprietary patented platform technology to develop therapies that elicit self-produced antibodies that block disease-causing proteins irrespective of their endogenous or exogenous origin.